Maxim Pharmaceuticals Inc. nailed down a potential $27 million licensing deal centered on its apoptosis-inducing cancer compounds with Myriad Genetics Inc. (BioWorld Today)
Discovery Laboratories Inc. reaped more good news with Surfaxin, which met statistical significance in the co-primary endpoints of a pivotal Phase III trial in premature infants afflicted with respiratory distress syndrome. (BioWorld Today)
About two years after signing a partnership for protein optimization with Eli Lilly and Co. - and less than a week after filing its first investigational new drug application for a compound being developed in-house - Applied Molecular Evolution Inc. has agreed to merge with Lilly in a deal expected to be worth about $400 million, net of cash. (BioWorld Today)
Age-related macular degeneration (AMD) is a demon of the elderly, snatching away their sight at a time in life when, for many, to watch the world is one of the great pleasures - a pleasure not afforded them in the busy, earlier years.
